Case Study – Rare-Disease

ODC Implemented a Three-Pillar Strategy to Unlock LATAM for a Global Ultra-Rare Kidney Disease Trial

Category: Case study
Reading Time: < 1 min

Challenge The sponsor needed to recruit patients with C3G and IC-MPGN — two ultra-rare complement-mediated kidney diseases — for the Phase III VALIANT trial evaluating pegcetacoplan. With an estimated incidence of 0.2–3 cases per million people and diagnosis requiring specialized renal biopsy with electron microscopy, identifying eligible patients in LATAM represented a major operational and clinical challenge.

Strategy

  • Omnichannel Physician Engagement: Presented at national nephrology congresses, disseminated via SBN mailing lists and WhatsApp networks, and launched a national rare disease registry with COMDORA.
  • Centralized Nephropathology Partnership: Partnered with Instituto de Nefropatologia (Brazil) — led by Dr. Stanley Araújo — conducting a nationwide retrospective review of renal biopsy archives and EMRs, identifying 230+ potential patients across Brazil and Argentina.
  • Senior Medical Advisor Network: Engaged Dr. Lilian Palma (Pediatric Nephrologist) and Dr. Stanley Araújo to activate investigator networks, support physician education, and build referral pathways across both countries.

Results & Why This Matters

  • ~20% of global VALIANT enrollment came from LATAM.
  • Brazil ranked #2 recruiting country worldwide, behind only the United States.
  • 230+ potential patients identified retrospectively across Brazil and Argentina and received a correct diagnosis.

VALIANT Trial Details The New England Journal of Medicine – Original Article Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN F. Fakhouri, A.S. Bomback, et al. for the VALIANT Trial Investigators Group* Pegcetacoplan was FDA-approved in 2025 for pediatric (first-ever) & adult patients with C3G/IC-MPGN.

Share

Also read

Brazil Case study Oncology

Case Study – Oncology

ODC Turned Brazil into the World's #1 Country for a Biomarker-Selected Global Precision Oncology Trial (GIST)
Read more
Case study

Case Study – Hematology

ODC Implemented a High-Touch Recruitment Model to Make Brazil a Decisive Late-Stage Accelerator in a Global Rare Hematology Trial
Read more

Sign up for our newsletter for the latest updates

Privacy Notice and Personal Data Processing

By submitting this form, you declare that you are aware that the personal data provided will be processed by ODC Life Sciences to receive, analyze, and respond to your request, make the necessary contacts, and, when applicable, comply with legal or regulatory obligations and exercise ODC’s rights.

When necessary for these purposes, the data may be shared with ODC Group companies and third parties involved in addressing the request, including service providers, partners, sponsors, or research centers, as applicable and in accordance with the principles and requirements set forth in the General Data Protection Law (Brazilian Law No. 13.709/2018 – LGPD).

ODC will adopt appropriate measures to protect the security and confidentiality of personal data and will retain it for the period necessary to fulfill the stated purposes and to comply with legal or regulatory obligations or for the regular exercise of rights.

For more information on the processing of personal data and on exercising the rights provided for in the LGPD (Brazilian General Data Protection Law), please consult the ODC Life Sciences Privacy Policy.

And add a mandatory checkbox for submitting the form, with the following phrase next to the checkbox: I have read and am aware of the Privacy Notice and Personal Data Processing Policy.